4.5 Article

Population-based Canadian hip fracture rates with international comparisons

期刊

OSTEOPOROSIS INTERNATIONAL
卷 21, 期 8, 页码 1317-1322

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s00198-009-1080-1

关键词

Epidemiology; Hip fractures; Osteoporosis

资金

  1. Merck Frosst Canada
  2. Sanofi-Aventis
  3. Procter & Gamble Pharmaceuticals Canada, Inc.
  4. Novartis Pharmaceuticals Canada, Inc.
  5. Amgen Canada
  6. Genzyme Canada Ltd
  7. Servier Canada Ltd.
  8. Eli Lilly Canada Ltd.
  9. Nycomed Canada Ltd.
  10. Pfizer Canada Ltd.
  11. GSK Canada Ltd.
  12. Biosante Ltd
  13. J and J Canada Ltd.
  14. Zelos Canada Ltd
  15. Merck Frosst
  16. Procter & Gamble Pharmaceuticals
  17. Procter Gamble

向作者/读者索取更多资源

We identified hospitalizations throughout Canada during 2000-2005 in which the most responsible diagnosis was a proximal femoral fracture. Use of the US fracture risk assessment tool (FRAX) would be inappropriate for Canada as it would overestimate fracture risk in Canadian women and older men. It is recommended that the WHO fracture risk assessment tool should be calibrated to the target population. We identified hospitalizations for women and men throughout Canada during the study period 2000-2005 in which the most responsible diagnosis was a proximal femoral fracture (147,982 hip fractures). Age-standardized hip fracture rates were compared between Canadian provinces, and national rates were compared with those reported for the USA and Germany. There were relatively small differences in hip fracture rates between provinces, and most did not differ appreciably from the Canadian average. Hip fracture rates for women in Canada in 2001 were substantially lower than in the USA (population-weighted rate ratio 0.70) and were also lower than in Germany for 2004 (population-weighted rate ratio 0.74). Overall hip fracture rates for Canadian women were found to be substantially lower than those for the USA and Germany. This study underscores the importance of assessing country-specific fracture patterns prior to adopting an existing FRAX tool.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据